Key Features Dual-mechanism design: GHRH-receptor agonism (CJC-1295) + GHSR agonism (Ipamorelin) for complementary GH-axis interrogation 99% Purity (HPLC/MS verified): Consistent material for reproducible protocols Protocol-friendly kinetics: Short, high-amplitude GH pulse (Ipamorelin) alongside prolonged GH/IGF-1 support (CJC-1295) in model systems GMP-compliant manufacturing (USA): Batch-to-batch reliability COA included: Full lot documentation Specifications Identity: CJC-1295 NO DAC /Ipamorelin USA cGMP Produced Form & Sizes: 10 mg or 20 mg blended vials Appearance: White to off-white lyophilized powder Purity: 99% (HPLC/MS verified) Manufacturing: GMP-compliant facility, USA Storage: 20 C, desiccated
Its long-term safety record is, by definition, thinner: semaglutide has been prescribed to millions and carries a large post-market safety database, while retatrutide's safety profile is still being characterized in ongoing trials
Be sure to follow the rules for medical content on the platform
adults (~32 million people) have taken GLP-1 medications ( [1] ), and roughly 4% of all Americans (~13 million) were on a GLP-1 drug in 2024 ( [2] )
In line with these recommendations, our meta-analysis corroborates the clinical benefits of both medications compared with placebo
Diabetes (1979) 28(12):11412
